Please login to the form below

progressive supranuclear palsy

This page shows the latest progressive supranuclear palsy news and features for those working in and with pharma, biotech and healthcare.

Roche pays $120m upfront for UCB’s anti-tau Alzheimer’s drug

The investigational treatment, UCB0107, is a monoclonal antibody drug being developed by UCB as a potential treatment for patients with tauopathies, such as progressive supranuclear palsy (PSP) and Alzheimer’s disease. ... Tau pathology is indicated in

Latest news

Biogen grows in Q2, but Spinraza performance a concern

Biogen has a number of significant clinical readouts over the next 18 months, but many of these remain high risk, such as the phase 3 trial of BIIB092 in progressive supranuclear ... palsy. One big binary decision awaiting the firm is a challenge
Spinraza keeps Biogen afloat as Tecfidra stalls

He adds: “By the end of 2020 we expect readouts across our clinical programmes in MS, progressive supranuclear palsy, ALS, Parkinson’s disease, pain, cognitive impairment associated with schizophrenia, epilepsy, stroke, ... Trial results of
Spinraza lifts Biogen ahead of Alzheimer’s data

enrolment in phase 2 studies of new MS therapy opicinumab and BIIB092 for progressive supranuclear palsy.
Celgene bulks up pipeline again with $2.1bn Prothena deal

The three targets at the centre of the collaboration with Ireland-based Prothena include: tau protein, already a focus in Alzheimer’s research and other conditions like progressive supranuclear palsy (PSP);
AbbVie takes anti-tau drug into phase II for Alzheimer's

drugs. The antibody - called ABBV-8E12 - is being tested in two phase II trials, one in patients with early Alzheimer's and a second in progressive supranuclear palsy (PSP), a rare ... We see potential in ABBV-8E12 and tau-focused approaches to

More from news
Approximately 1 fully matching, plus 8 partially matching documents found.

Latest Intelligence

Deal Watch - May 2017

BMS. Biogen (US). Licence. Anti-tau antibody pre phase 2 for progressive supranuclear palsy.
Deal Watch table for April 2014

750. iPerian/ BMS. Acquisition. CNS/ Tauopathies, mAB IPN007 to treat progressive supranuclear palsy (PSP) (preclinical).

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Healthcare Senior Account Manager: Competitive

Account Director – Creative Healthcare Communications: Competative

Sales Director, Healthcare communications agency, London/ SE UK: Six figure salary

Healthcare Account Director: Competitive

Medical Editor: Competitive

Healthcare Lead Copywriter: Competitive

Account Manager Healthcare / Pharmaceutical Sector: Negotiable Salary

PMHub

Add my company

Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

AstraZeneca’s focus on diagnosing and managing chronic kidney disease: People living with chronic kidney disease are in urgent need of new and improved approaches to diagnosis and care...
Delphi Technique Virtual Co-creation: A Customer Story: How a client leveraged the Delphi technique to co-create a consensus statement and algorithm using virtual touchpoints....
Three ways AI will change healthcare in the next decade: Looking forward, there is no doubt that AI will continue to take centre stage in global healthcare initiatives...